Zobrazeno 1 - 10
of 2 130
pro vyhledávání: '"Guru Murthy"'
Autor:
Alexandra E. Rojek, Benjamin J. McCormick, Joanna Cwykiel, Oluwatobi Odetola, Yasmin Abaza, Nhi Nai, Charles E. Foucar, Rohan K. Achar, Rory M. Shallis, Danielle Bradshaw, Meaghan Standridge, Vamsi Kota, Guru Subramanian Guru Murthy, Talha Badar, Anand A. Patel
Publikováno v:
eJHaem, Vol 5, Iss 4, Pp 728-737 (2024)
Abstract Core‐binding factor acute myeloid leukemia (CBF‐AML) is characterized by the presence of inv(16)/t(16;16) or t(8;21) and is classified as a favorable risk by the 2022 European LeukemiaNet (ELN) guidelines. The CD33‐targeting antibody
Externí odkaz:
https://doaj.org/article/1bfdcf9f323e452da7d543f9693d2ac5
Autor:
Talha Badar, Ahmad Nanaa, Ehab Atallah, Rory M. Shallis, Sacchi de Camargo Correia Guilherme, Aaron D. Goldberg, Antoine N. Saliba, Anand Patel, Jan P. Bewersdorf, Adam S. DuVall, Danielle Bradshaw, Yasmin Abaza, Guru Subramanian Guru Murthy, Neil Palmisiano, Amer M. Zeidan, Vamsi Kota, Mark R. Litzow
Publikováno v:
Blood Cancer Journal, Vol 14, Iss 1, Pp 1-4 (2024)
Externí odkaz:
https://doaj.org/article/768054ee7a0b494192b71e0f348ee872
Autor:
Guru Subramanian Guru Murthy, Tao Zhang, Yung-Tsi Bolon, Stephen Spellman, Jing Dong, Paul Auer, Wael Saber
Publikováno v:
Biomarker Research, Vol 12, Iss 1, Pp 1-4 (2024)
Abstract Disease relapse remains a major barrier to success after allogeneic hematopoietic cell transplantation (allo-HCT) in myelodysplastic neoplasms (MDS). While certain high risk genomic alterations are associated with increased risk of relapse,
Externí odkaz:
https://doaj.org/article/4237d40728e34d7aa04b78365928ddf2
Autor:
Furqan, Fateeha, Bhatlapenumarthi, Vineel, Dhakal, Binod, Fenske, Timothy S., Farrukh, Faiqa, Longo, Walter, Akhtar, Othman, D’Souza, Anita, Pasquini, Marcelo, Guru Murthy, Guru Subramanian, Runaas, Lyndsey, Abedin, Sameem, Mohan, Meera, Shah, Nirav N., Hamadani, Mehdi
Publikováno v:
In Blood Advances 27 August 2024 8(16):4320-4329
Autor:
Patel, Anand A., Yoon, James J., Johnston, Hannah, Davidson, Marta B., Shallis, Rory M., Chen, Evan C., Burkart, Madelyn, Oh, Timothy S., Iyer, Sunil G., Madarang, Ellen, Muthiah, Chandrasekar, Gross, Iyana, Dean, Raven, Kassner, Joshua, Viswabandya, Auro, Madero-Marroquin, Rafael, Rampal, Raajit K., Guru Murthy, Guru Subramanian, Bradley, Terrence, Abaza, Yasmin, Garcia, Jacqueline S., Gupta, Vikas, Pettit, Kristen M., Cursio, John F., Odenike, Olatoyosi
Publikováno v:
In Blood Advances 9 July 2024 8(13):3468-3477
Autor:
Talha Badar, Ahmad Nanaa, Ehab Atallah, Rory M. Shallis, Emily C. Craver, Zhuo Li, Aaron D. Goldberg, Antoine N. Saliba, Anand Patel, Jan P. Bewersdorf, Adam Duvall, Madelyn Burkart, Danielle Bradshaw, Yasmin Abaza, Maximilian Stahl, Neil Palmisiano, Guru Subramanian Guru Murthy, Amer M. Zeidan, Vamsi Kota, Mrinal M. Patnaik, Mark R. Litzow
Publikováno v:
Haematologica, Vol 999, Iss 1 (2024)
While there is clear evidence to suggest poorer outcome associated with multi-hit (MH) TP53 mutation compared to single-hit (SH) in lower-risk myelodysplastic syndrome (MDS), data are conflicting in both higher-risk MDS and acute myeloid leukemia (AM
Externí odkaz:
https://doaj.org/article/c1694d4dbade4d11b7fd3ea5b5113ad5
Autor:
Guru Subramanian Guru Murthy, Antoine N. Saliba, Aniko Szabo, Alexandra Harrington, Sameem Abedin, Karen Carlson, Laura Michaelis, Lyndsey Runaas, Arielle Baim, Alex Hinman, Sonia Maldonado-Schmidt, Annapoorna Venkatachalam, Karen S. Flatten, Kevin L. Peterson, Paula A. Schneider, Mark Litzow, Scott H. Kaufmann, Ehab Atallah
Publikováno v:
Haematologica, Vol 999, Iss 1 (2024)
Azacitidine/venetoclax is an active regimen in patients with newly diagnosed AML. However, primary or secondary resistance to azacitidine/venetoclax is an area of unmet need and overexpression of MCL-1 is suggested to be a potential resistance mechan
Externí odkaz:
https://doaj.org/article/950acd891d7543f3b377e2a769eccff7
Autor:
Muthiah, Chandrasekar, Narra, Ravi, Atallah, Ehab, Juan, Wanlin, Szabo, Aniko, Guru Murthy, Guru Subramanian
Publikováno v:
In Leukemia Research May 2024 140
Autor:
Guru Murthy GS
Publikováno v:
Blood and Lymphatic Cancer: Targets and Therapy, Vol Volume 12, Pp 1-6 (2022)
Guru Subramanian Guru Murthy Division of Hematology & Oncology, Medical College of Wisconsin, Milwaukee, WI, USACorrespondence: Guru Subramanian Guru Murthy, Division of Hematology & Oncology, Medical College of Wisconsin, Milwaukee, WI, USA, Tel +1
Externí odkaz:
https://doaj.org/article/9717cab076284ac79a9383279703fd96